UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000005042
Receipt number R000005974
Scientific Title Gemcitabine/TS-1 combination chemoradiotherapy for unresectable locally advanced pancreatic cancer(Phase I study)
Date of disclosure of the study information 2011/02/07
Last modified on 2017/05/16 19:16:00

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Gemcitabine/TS-1 combination chemoradiotherapy for unresectable locally advanced pancreatic cancer(Phase I study)

Acronym

Phase I study of CRT+GS for PC

Scientific Title

Gemcitabine/TS-1 combination chemoradiotherapy for unresectable locally advanced pancreatic cancer(Phase I study)

Scientific Title:Acronym

Phase I study of CRT+GS for PC

Region

Japan


Condition

Condition

Unresectable locally advanced pancreatic cancer

Classification by specialty

Hepato-biliary-pancreatic medicine Hepato-biliary-pancreatic surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the clinical safety and efficacy of Gemcitabine/TS-1 combination chemoradiotherapy and to determine the MTD for unresectable locally advanced pancreatic cancer

Basic objectives2

Safety

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Phase I


Assessment

Primary outcomes

Safety

Key secondary outcomes

Efficacy, Median survival time (MST), Palliative efficacy


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Gemcitabine is administered with 30 min intravenous infusion on day 1 and 8 every 3 weeks.
TS-1 60mg/m2/day is administered orally for 2 consecutive weeks every 3 weeks.
Concurrent radiotherapy (a total dose of 50.4Gy) was delivered in 28 fractions.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

75 years-old >

Gender

Male and Female

Key inclusion criteria

1.Histologically or cytologically confirmed advanced pancreatic cancer
2.Locally advanced pancreatic cancer is defined as the presence of a surgically unresectable tumor(involving the celiac axis or the superior mesenteric artery)
3.Performance Status:0-1(ECOG)
4.Patients of age =>20 and 75>
5.WBC>=3,500/mm3,12,000/mm3,
neutrophils >=1,500/mm3, platelets=100,000/mm3,
hemoglobin >=9.5 g/dl,
GOT </=2.0 X ULN,
GPT </=2.0 X ULN,
AL-P </=2.0 X ULN,
total bilirubin <=1.5mg/dl,
serum creatinine <=1.2mg/dl,
creatinine clearance>=50 ml/min
6.Life expectancy more than 3 months.
7.Written informed consent.

Key exclusion criteria

1.Active infection
2.Lung fibrosis or intestinal pneumoni detectable on chest X-ray and CT
3.Severe complication (heart disease, cirrhosis, diabetes)
4.Myocardial infarction within 3 months
5.Active synchronous or metachronous malignancy
6.Pregnant or lactation women, or women with known or suspected pregnancy 7.Symptomatic brain metastasis
8.history of severe drug allergy
9.Patients who are judged inappropriate for the entry into the study by the investigater

Target sample size

24


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Tatsuya Ioka

Organization

Osaka Medical Center for Cancer and Cardiovascular Diseases

Division name

Division of Hepatobiliary and Pancreatic Oncology

Zip code


Address

3-3 Nakamichi 1cho-me, Higashinari-ku Osaka, Japan

TEL

06-6945-1181

Email

ioka_ta@hotmail.com


Public contact

Name of contact person

1st name
Middle name
Last name Tatsuya Ioka

Organization

Osaka Medical Center for Cancer and Cardiovascular Diseases

Division name

Division of Hepatobiliary and Pancreatic Oncology

Zip code


Address

3-3 Nakamichi 1cho-me, Higashinari-ku Osaka, Japan

TEL

06-6945-1181

Homepage URL


Email

ioka_ta@hotmail.com


Sponsor or person

Institute

Osaka Medical Center for Cancer and Cardiovascular Diseases
Division of Hepatobiliary and Pancreatic Oncology

Institute

Department

Personal name



Funding Source

Organization

Osaka foundation for the prevention of cancer and cardiovascular diseases

Organization

Division

Category of Funding Organization

Non profit foundation

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2011 Year 02 Month 07 Day


Related information

URL releasing protocol


Publication of results

Partially published


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2006 Year 10 Month 31 Day

Date of IRB


Anticipated trial start date

2006 Year 12 Month 01 Day

Last follow-up date

2010 Year 12 Month 01 Day

Date of closure to data entry

2011 Year 01 Month 01 Day

Date trial data considered complete

2011 Year 02 Month 01 Day

Date analysis concluded

2011 Year 02 Month 01 Day


Other

Other related information



Management information

Registered date

2011 Year 02 Month 07 Day

Last modified on

2017 Year 05 Month 16 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000005974


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name